Skip to main content
. 2020 Jul 24;62:e52. doi: 10.1590/S1678-9946202062052

Table 5. Relative risk of negative serology after benznidazole treatment.

  • Study

  • Experimental

  • Control

  • Weight

  • RR

  • 95%CI

 

  • Events

  • Total

  • Events

  • Total

  • Laucella et al.24

  • Viotti et al.31

  • Viotti et al.32

  • Torrico et al.30

  • Total (95% CI)

  • Total events

  • 6

  • 32

  • 21

  • 5

  • 64

  • 43

  • 218

  • 53

  • 45

  • 359

  • 1

  • 12

  • 6

  • 2

  • 21

  • 32

  • 212

  • 89

  • 89

  • 422

  • 5.2%

  • 54.8%

  • 31.3%

  • 8.7%

  • 4.47 [0.57; 35.28]

  • 2.59 [1.37; 4.90]

  • 5.88 [2.53; 13.63]

  • 4.94 [1.00; 24.49]

  • 3.65 [2.28; 5.84]

graphic file with name 1678-9946-rimtsp-62-S1678-9946202062052-e03.jpg
Heterogeneity: I2 = 0%, t2 = 0, p = 0.47